Cargando…
PTPRZ1-METFUsion GENe (ZM-FUGEN) trial: study protocol for a multicentric, randomized, open-label phase II/III trial
BACKGROUND: PTPRZ1-MET fusion was reported to associate with glioma progression from low-grade to high-grade glioma, which was a target by a MET inhibitor vebreltinib. However, little is known about the further efficacy of vebreltinib among more glioma patients. This trial aims to evaluate the safet...
Autores principales: | Bao, Zhaoshi, Li, Shouwei, Wang, Liang, Zhang, Bisi, Zhang, Peilong, Shi, Hepeng, Qiu, Xiaoguang, Jiang, Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347714/ https://www.ncbi.nlm.nih.gov/pubmed/37443050 http://dx.doi.org/10.1186/s41016-023-00329-0 |
Ejemplares similares
-
Tackling CASMI 2012: Solutions from MetFrag and MetFusion
por: Ruttkies, Christoph, et al.
Publicado: (2013) -
Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth
por: Shi, Yu, et al.
Publicado: (2017) -
Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells
por: Fujikawa, Akihiro, et al.
Publicado: (2017) -
Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme
por: Chen, Bao-Shi, et al.
Publicado: (2020) -
PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma
por: Makinoshima, Hideki, et al.
Publicado: (2012)